Benjamin J. Hindson Cashes Out 2388 Shares of 10x Genomics, Inc
June 21, 2023
☀️Trending News
Benjamin J. Hindson has recently sold 2388 shares of 10x Genomics ($NASDAQ:TXG), Inc. (TXG). 10x Genomics is a publicly traded company based in Pleasanton, California that specializes in single-cell sequencing technologies. They offer products and services in the fields of life sciences, genetics, and genomics. 10x Genomics also provides solutions for researchers to study genetic diversity, investigate disease, and advance personalized medicine.
They have developed unique tools for clinical diagnostics and drug discovery. 10x Genomics’ technology portfolio enables researchers to uncover the complex structures of cells and organisms at a deeper level than ever before. With this technology, researchers will be able to gain valuable insights into the biology of cells, and unlock the full potential of single-cell sequencing technology.
Stock Price
On Tuesday, 10X GENOMICS stock opened at $54.1 and closed at $54.1, up by 2.3% from last closing price of 52.9. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for 10x Genomics. More…
| Total Revenues | Net Income | Net Margin |
| 536.2 | -174.33 | -32.5% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for 10x Genomics. More…
| Operations | Investing | Financing |
| -33.61 | -350.89 | 15.82 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for 10x Genomics. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 1.01k | 211.65 | 6.78 |
Key Ratios Snapshot
Some of the financial key ratios for 10x Genomics are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 26.6% | – | -31.6% |
| FCF Margin | ROE | ROA |
| -30.8% | -13.2% | -10.5% |
Analysis
At GoodWhale, we’ve conducted an analysis of 10X GENOMICS‘ financials and believe their Star Chart score of 4/10 indicates an intermediate health score with regard to their cashflows and debt. This suggests they’re likely to safely ride out any crisis without the risk of bankruptcy. In terms of strengths and weaknesses, 10X GENOMICS is strong in asset and growth but weak in dividend and profitability. As such, we classify 10X GENOMICS as a ‘cheetah’. This type of company has achieved high revenue or earnings growth but is considered less stable due to lower profitability. Given these factors, investors who are comfortable with a higher risk-reward ratio may be interested in 10X GENOMICS, as the potential rewards could be higher than the risks. Those looking for a more stable investment may want to look elsewhere. More…
Peers
The company’s products include the Chromium System, an integrated solution for genome sequencing and data analysis, and the Visium Spatial Transcriptomics System, amicroarray platform for analyzing transcriptome activity in tissue samples. 10x Genomics has raised $310 million in funding from investors such as Fidelity Investments, Kleiner Perkins, and Google Ventures. 10x Genomics’ main competitors are Certara Inc, Omnicell Inc, and CardioComm Solutions Inc. These companies offer similar products and services to support genomic research.
– Certara Inc ($NASDAQ:CERT)
Certara Inc is a biopharmaceutical company that uses data and technology to improve drug development decisions. The company has a market cap of 2.49B as of 2022 and a Return on Equity of 1.81%. The company’s products and services are used by pharmaceutical, biotechnology, and medical device companies, as well as academic institutions and government agencies.
– Omnicell Inc ($NASDAQ:OMCL)
Omnicell is a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies. Their market cap of 2.49B as of 2022, and ROE of 2.67% indicates a strong and growing company. Omnicell provides solutions that help increase patient safety and improve medication adherence. Their products are used in a variety of settings, including hospitals, long-term care facilities, and retail pharmacies.
– CardioComm Solutions Inc ($TSXV:EKG)
CardioComm Solutions Inc is a medical device company that provides cardiac monitoring and arrhythmia detection solutions. It has a market cap of 2.26M as of 2022 and a return on equity of -59.73%. The company’s products are used in hospitals, clinics, and by individual patients for the remote monitoring of cardiac activity.
Summary
10X Genomics is a biotechnology company that offers genomics solutions for research and clinical applications. Benjamin J. Hindson recently sold 2388 shares of the company, indicating his belief that the price of 10X Genomics stock will soon decrease. Investors should be aware that 10X Genomics faces competition from other companies in the same space and that its stock performance has been volatile. The company has strong fundamentals, including an impressive revenue growth rate and high gross margins.
Furthermore, 10X Genomics has seen increased interest from institutional investors in recent quarters. Given these factors, investors may want to keep an eye on 10X Genomics and its stock performance.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
